IriSys and Xcelience have entered into a business alliance agreement to advance the ability to streamline access to CMC and regulatory expertise for North American pharmaceutical and biotechnology companies.
“IriSys has considerable experience moving compounds from early research to Phase I/II clinical trials in addition to offering full regulatory and strategic planning services”
"IriSys has considerable experience moving compounds from early research to Phase I/II clinical trials in addition to offering full regulatory and strategic planning services," says Derek Hennecke, CEO & President of Xcelience. "This alliance provides a unique opportunity to leverage these strengths in conjunction with our own in a way that minimizes client risk, and maximizes client accessibility to the strategic locations of each company on the east and west coasts of the U.S."
"Xcelience has a solid industry-wide reputation for accelerating the early drug development process; their particular solid dosage form technology expertise in filling an active pharmaceutical ingredient into capsules and their outstanding project management system are certainly complementary to IriSys," says Gina Stack, President & CEO of IriSys. "Our common philosophy, organizational culture, and inherent commitment to quality make the alliance a natural fit."
New research reveals why fiber-rich diets fuel you better than refined foods